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CathepsinThe underlying mechanisms of cardiotoxicity of 3,4-methylenedioxymethylamphetamine (MDMA, “ecstasy”)
abuse are unclear. Autophagy exerts either adaptive or maladaptive effects on cardiac function in various patho-
logical settings, but nothing is known on the role of autophagy in theMDMA cardiotoxicity. Here,we investigated
the mechanism through which autophagy may be involved in MDMA-induced cardiac contractile dysfunction.
Rats were injected intraperitoneally with MDMA (20 mg/kg) or saline. Left ventricular (LV) echocardiography
and LV pressure measurement demonstrated reduction of LV systolic contractility 24 h after MDMA administra-
tion. Western blot analysis showed a time-dependent increase in the levels of microtubule-associated protein
light chain 3-II (LC3-II) and cathepsin-D after MDMA administration. Electron microscopy showed the presence
of autophagic vacuoles in cardiomyocytes. MDMA upregulated phosphorylation of adenosine monophosphate-
activated protein kinase (AMPK) at Thr172, mammalian target of rapamycin (mTOR) at Thr2446, Raptor at
Ser792, and Unc51-like kinase (ULK1) at Ser555, suggesting activation of autophagy through the AMPK-mTOR
pathway. The effects of autophagic inhibitors 3-methyladenine (3-MA) and chloroquine (CQ) on LC3-II levels in-
dicated that MDMA enhanced autophagosome formation, but attenuated autophagosome clearance. MDMA also
induced release of cathepsins into cytosol, and western blotting and electron microscopy showed cardiac tropo-
nin I (cTnI) degradation andmyoﬁbril damage, respectively. 3-MA, CQ, and a lysosomal inhibitor, E64c, inhibited
cTnI proteolysis and improved contractile dysfunction after MDMA administration. In conclusion, MDMA causes
lysosome destabilization following activation of the autophagy-lysosomal pathway, through which released
lysosomal proteases damage myoﬁbrils and induce LV systolic dysfunction in rat heart.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Sudden death after abuse of 3,4-methylenedioxymethylam-
phetamine (MDMA, “ecstasy”) is not uncommon. In forensic practice,
sudden cardiac death after the ﬁrst abuse of MDMA or other amphet-
amines [1] has been seen, and thus it is important to examine how a sin-
gle MDMA injection affects cardiac function. Autopsy and case reportsphetamine; LV, left ventricular;
K, adenosine monophosphate-
rapamycin; ULK1, Unc51-like
rdiac troponin I; PLN, phospho-
eptor; HR, heart rate; SERCA2a,
c blood pressure; DBP, diastolic
meter; LVESD, left ventricular
rior wall thickness; LVEDV, left
end-systolic volume; LV FS, left
ction fraction; BT, body temper-
saline with Tween-20
81 3 5841 3366.
ida).
ights reserved.on MDMA-related deaths have documented cardiomyocyte necrosis
with inﬂammatory responses [2,3], dilated cardiomyopathy [4] or cardi-
ac hypertrophy [5], and the mechanism underlying the cardiotoxicity
of MDMA has been examined in a few animal studies. For example,
repeated binge administration ofMDMA to rats led to eccentric left ven-
tricular (LV) dilation and contractile dysfunction through nitration of
contractile-related proteins [6], while single administration of MDMA
to rat induced oxidative stress and myocardial contraction band necro-
sis with macrophage inﬁltration [7].
In both humans [8] and rat [9], MDMA is initially metabolized to
3,4-dihydroxymethamphetamine (DHMA) and 3,4-methylenedioxyam-
phetamine (MDA) through pathways of O-demethylenation and N-
demethylation, respectively, in the liver. MDA further undergoes O-
demethylenaton to form 3,4-dihydroxyamphetamine (DHA). DHMA and
DHA can generate reactive oxygen species (ROS) in subsequent oxidation
reactions to corresponding quinones [10]. In adult rat cardiomyocytes,
DHMA and DHA rather than MDMA per se exerts cardiotoxicity through
oxidative stress [10,11].
Lysosomes are highly dynamic organelles that receive and degrade
macromolecules from the endocytotic, phagocytic and autophagic
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pool of redox-active iron can produce ROS through catalyzing a Fenton
reaction, thereby amplifying ROS generation in response to ROS derived
fromoutside lysosomes. The resulting, peroxidation of lipids in the lyso-
somal limiting membrane causes destabilization of these membranes.
Subsequent release of enzymes such as cathepsins from lysosomes
damage adjacent mitochondria, leading to excessive ROS generation
and impaired ATP production (for a review, see [13]). Consistent with
this hypothesis, MDMA-induced ROS production, lysosomal and mito-
chondrial damage and necrosis are prevented by lysosomotropic agents
[14].
Autophagy is a vital homeostatic turnover process, in which long-
lived proteins, degenerated proteins and damaged organelles undergo
lysosomal degradation for maintenance of homeostasis and survival.
Upon initiation of autophagy, a small vesicular sac (“phagophore”) elon-
gates and subsequently encloses a portion of cytoplasm, which results
in formation of autophagosomes (for a review, see [15,16]). In
phagophore elongation, microtubule-associated protein light chain 3
(LC3) is lipidated, which can be detected as the change from LC3-I to
LC3-II (from slower to faster migration) in western blot analysis. LC3
is thus used as a marker for autophagosomes. The autophagosome
then fuses with a lysosome to form an autolysosome, leading to degra-
dation of the enclosed materials. Another possible autophagic marker,
p62/SQSTM1, is incorporated into the completed autophagosomes and
degraded in autolysosomes [17].
In the heart, autophagy occurs constitutively in the normalmyocardi-
um, but exerts either adaptive/compensatory ormaladaptive/deleterious
effects on cardiac function and remodeling, depending on particular
pathological settings. For example, autophagy prevents left ventricular
dysfunction and dilatation in mice subjected to pressure overload [18],
myocardial infarction [19] and starvation [20]. Conversely, excessive au-
tophagy in mice with Beclin 1 overexpression accentuated pathological
remodeling in pressure overload [21]. Recent studies showed that etha-
nol intake induces cardiac contractile dysfunction due to accumulation
of autophagosomes [22,23]. However, the involvement of autophagy in
MDMA-induced cardiotoxicity has not been investigated.
Mammalian target of rapamycin complex 1 (mTORC1) negatively
regulates autophagy, and inhibition of mTOR leads to autophagy induc-
tion [24]. mTORC1 is activated by Akt-mediated mTOR phosphorylation
at Ser2448 or Ser2441 [25]. In contrast, mTORC1 is inactivated through
adenosine monophosphate-activated protein kinase (AMPK)-mediated
phosphorylation at Thr2446 [26]. Besides the direct phosphorylation of
mTOR, AMPK can inhibit mTOR through phosphorylation of Raptor at
Ser792 [27] and Unc51-like kinase (ULK1) at multiple sites including
Ser317, Ser467, Ser555, Thr575, Ser637 and Ser777 [28,29].
The aim of the current study was to investigate whether the
autophagy-lysosomal pathway affects cardiac function after single ad-
ministration ofMDMA in rats.We found that coordination of autophagy
upregulation and lysosome destabilization causes MDMA-induced con-
tractile dysfunction.
2. Materials and methods
2.1. Animal protocols
The study was performed according to the Guide for the Care and
Use of Laboratory Animals (NIH publication 85–23, revised 1996) and
was approved by the Institutional Animal Care and Use Committee
of the University of Tokyo. MDMA (20 mg/kg) or saline was admin-
istered intraperitoneally to 7-week-old male Sprague-Dawley rats.
In separate experiments, an autophagy inhibitor, 3-methyladenine
(3-MA; 15 mg/kg in saline; Sigma-Aldrich, St Louis, MO) or chloro-
quine (CQ; 20 mg/kg in saline; Wako Pure Chemical Industries,
Osaka, Japan), or a cysteine protease inhibitor, E64c [30] (10 mg/kg
in saline; Peptide Institute, Osaka, Japan) was injected intraperitone-
ally 1 h before MDMA administration.2.2. Physiological studies
Twenty-four hours after MDMA administration, heart rate (HR) and
blood pressure (systolic blood pressure, SBP; diastolic blood pressure,
DBP) were measured using the tail-cuff method after warming the ani-
mal (Softron, Tokyo, Japan). Echocardiographic assessment was then
performed under inhalational anesthesia (1.5 L/min)with 2% isoﬂurane
(Mylan, Canonsburg, PA), using ProSound α10 (Hitachi Aloka Medical,
Tokyo, Japan) equipped with a 5–7.5 MHz linear transducer (UST-
536). An adequate depth of anesthesiawasmaintainedwithmonitoring
using the toe reﬂex. A two-dimensional (2D) parasternal short-axis
view of the left ventricle (LV) was obtained at the level of the papillary
muscles. The sweep speedwas 200mm/s inM-mode. Acquisition of the
viewwas repeated 5 times for each examination. LV end-diastolic diam-
eter (LV EDD), LV end-systolic diameter (LV ESD) and diastolic LV pos-
terior wall thickness (PW) were measured; LV end-diastolic volume
(LV EDV) and LV end-systolic volume (LV ESV) were calculated as (LV
EDD)3 and (LV ESD)3, respectively, according to Pombo's formula [31];
LV fractional shortening (LV FS) and LV ejection fraction (LV EF) were
calculated as [(LV EDD-LV ESD)/LV EDD] × 100 (%) and [(LV EDV-LV
ESV)/LV EDV] × 100 (%), respectively. All measurements were per-
formed on a distinct cardiac cycle picked from each view and the values
obtained from 5 views were averaged in each examination. Body tem-
perature (BT) was measured in the rectum during the echocardiogra-
phy. After echocardiography, the heart was harvested and the left
ventricle was immediately frozen in liquid nitrogen and stored at
−80 °C until western blot analysis.
In separate experiments, LV pressure was measured 24 h after
MDMA administration. Rats were anesthetized and ventilated using a
rodent ventilator. After left thoracotomy, a 1.9-Fr pressure–volume
catheter (Scisense, London, ON, Canada) was inserted into the LV
through a path made in the apex by punctuation using a 23-gauge nee-
dle. The parameters were acquired using a PowerLab data acquisition
system and analyzed using LabChart software (ADInstruments Japan,
Nagoya, Japan).
2.3. Western blot analysis
Tissue (0.1 g) was homogenized in 2 ml of an ice-cold solution of
320 mM sucrose, 10 mM Tris–HCl (pH 7.4), 1 mM EDTA, 50 mM NaF,
1 mM Na3VO4, and Complete Protease Inhibitor Cocktail (Roche Diag-
nostics, Mannheim, Germany). For evaluation of cathepsin release
from lysosomes and Bax translocation to the mitochondria, the homog-
enatewas centrifuged at 100,000 ×g for 60min at 4 °C. The resulting su-
pernatant and pellet were conﬁrmed as the cytosolic fraction and the
heavy membrane fraction containing the mitochondria, respectively,
by western blot analysis using antibodies to GAPDH (cytosolic marker)
and VDAC (mitochondrial marker) (Fig. 7B). These crude subcellular
fractions were solubilized in Laemmli sample buffer and 1 M NaOH for
SDS-PAGE and protein quantitation, respectively. Protein concentration
was determined with a Coomassie Protein Assay Kit (Thermo Fisher
Scientiﬁc, Waltham, MA).
In immunoblot analysis, the tissue homogenate or subcellular frac-
tion (25 μg of protein) was subjected to SDS-PAGE on 12.5% gels for
LC3, cathepsin-D, actin, AMPK, Akt, Beclin 1, p62/SQSTM1, cathepsin-
B, GAPDH and VDAC1/Porin; on 5% gels for mTOR, Raptor and ULK1;
on 6.5% gels for α-fodrin; or on 15% gels for cardiac troponin I (cTnI),
Bid and Bax. Blots were probed with antibodies speciﬁc for LC3
(#2775), cathepsin-D (#2284), total (#2280) or phospho (p)-
(Ser792, #2083) Raptor, total (#8054) or p- (Ser555, #5869) ULK1,
total (#2532) or p- (Thr172, #2535) AMPKα, total (#9272) or p-
(Ser473, #9271) Akt, total (#4517) or p- (Ser2448, #2971) mTOR,
Beclin 1 (#3495; Cell Signaling Technology Japan, Tokyo, Japan),
cathepsin-B (#sc-13985), Bid (#sc-11423), Bax (#sc-526; Santa Cruz
Biotechnology, Santa Cruz, CA), actin (#A2066; Sigma-Aldrich, St.
Louis, MO), p-mTOR (Thr2446, #ab63552), VDAC/Porin (#ab14734;
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Laboratories, Nagoya, Japan), cTnI (#MAB3150; Merck Millipore, Biller-
ica, MA), α-fodrin (#610013; Biohit, Helsinki, Finland), or GAPDH
(#G041; Applied Biological Materials, Richmond, BC). These primary
antibodies were diluted 1000 times with 1% bovine serum albumin in
Tris-buffered saline with Tween-20 (BSA/TBS-T) or by a signal enhanc-
er, HIKARI (Nacalai tesque, Kyoto Japan). Immune complexes were
detected with HRP-conjugated goat antibodies to mouse or rabbit IgG
(1:5000 dilution with 1% BSA/TBS-T; Promega, Madison, WI) and
chemiluminescence reagents (Western Lightning-ECL; PerkinElmer,
Waltham, MA). Band intensities were measured by using ImageQuant
™ LAS 4000 mini (GE Healthcare, Little Chalfont, England).
2.4. Electron microscopy
Cardiac tissue was rapidly cut into 1-mm cubes, immersion-ﬁxed in
2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) overnight at
4 °C, and post-ﬁxed in 1% buffered osmium tetroxide. The specimens
were then dehydrated through a graded ethanol series and embedded
in epoxy resin. Ultrathin sections (90 nm) double-stained with uranyl
acetate and lead citratewere examined by using an electronmicroscope
(H-800; Hitachi, Tokyo, Japan).
2.5. Measurement of serum MDMA and metabolite concentrations
The concentrations of MDMA and its metabolites, DHMA and DHA,
were measured in serum from rats 4 h after MDMA administration
using liquid chromatography–tandem mass spectrometry (LC–MS/
MS). Since DHMA and DHA also occur in serum as glucuronide and/or
sulfate conjugates [9], the samples were analyzed after hydrolysis.
Sample preparation and the instrument conditions for the analysis are
described in the Supplementary methods online.
2.6. Statistical analysis
Quantitative data are presented as means ± SE and were analyzed
by Dunnett test to compare each of several treatments with a single
control, Tukey–Kramer test to compare all possible pairs of groups,
and Student t-test to compare two groups. ANOVA was performed
before the Dunnett and Tukey–Kramer tests. dT (mmHg b 0.05was con-
sidered statistically signiﬁcant.Table 1
Biometric, echocardiographic and left ventricular pressure parameters in MDMA-injected
and pair-fed rats.
Saline MDMA Pair-feeding
Food intake (g) 24.0 ± 0.4 19.6 ± 0.8 ⁎⁎ –
BT (°C) 37.6 ± 0.2 38.1 ± 0.1 37.6 ± 0.2
HR (beats/min) 381 ± 12 398 ± 14 390 ± 7
SBP (mmHg) 95.5 ± 2.6 118.5 ± 10.5 99.8 ± 3.4
DBP (mmHg) 58.6 ± 2.8 72.0 ± 5.9 60.4 ± 2.9
LV EDD (mm) 6.72 ± 0.12 6.71 ± 0.20 6.92 ± 0.10
LV ESD (mm) 3.03 ± 0.06 3.75 ± 0.10 ⁎⁎ 3.05 ± 0.08
PW (mm) 2.17 ± 0.24 2.05 ± 0.21 2.06 ± 0.16
LV EDV (μl) 306 ± 15 308 ± 27 334 ± 14
LV ESV (μl) 31.1 ± 1.7 54.5 ± 4.1 ⁎⁎ 34.9 ± 3.2
LV FS (%) 54.8 ± 0.4 44.4 ± 0.8 ⁎⁎ 55.9 ± 0.7
LV EF (%) 90.7 ± 0.3 82.3 ± 0.8 ⁎⁎ 91.3 ± 0.4
LVDP (mmHg) 91.5 ± 5.8 57.7 ± 6.2 ⁎⁎ n.d.
LVEDP (mmHg) 1.95 ± 1.78 3.64 ± 0.89 n.d.
+ dP/dT (mmHg/s) 6629 ± 681 2933 ± 550 ⁎⁎ n.d.
− dP/dT (mmHg/s) −4834 ± 525 −2086 ± 603 ⁎⁎ n.d.
τ (ms) 8.14 ± 1.39 8.46 ± 2.23 n.d.
The parameters were measured 24 h after saline or MDMA injection, or after food restric-
tion to 18 g for 24 h following saline injection. n.d., not done. Data are shown as means±
SE (n=6 in biometry and echocardiography, andn=5 in LVpressuremeasurement) and
were analyzed by Dunnett test, except for food intake and LV pressure, which were com-
pared between the saline and MDMA groups by Student t-test. **P b 0.01 vs. saline-
injected rats.3. Results
3.1. MDMA induces left ventricular contractile dysfunction
Twenty-four hours after MDMA administration in rats, BT, HR, SBP
andDBP increased comparedwith those of control rats injectedwith sa-
line, but these changes were not signiﬁcant (Table 1). MDMA signiﬁ-
cantly increased LV ESD, but did not affect LV EDD or PW (Table 1).0
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Fig. 1. Western blot analyses of LC3 and cathepsin-D, and electron microscopy after
MDMA administration. Panel A shows representative blots of LC3 and cathepsin-D
(mature single chain form of 44 kDa), and quantitative data. The intensities of the bands
for LC3-I, LC3-II and cathepsin were determined as percentages of the corresponding
values for saline-injected rats. Actin was used as the loading control. PF, pair-fed for 24
h. Data are means ± SE (n = 6 rats). *P b 0.05, **P b 0.01 vs. saline-injected rats; n.s.,
not signiﬁcant (Dunnett test). Panel B shows an electron micrograph of cardiomyocytes
24 h after saline orMDMA injection. Autophagic vacuoles (arrows) containingmitochondria
(M) and myelin-like structures (arrowheads) were observed in MDMA-administrated rat
cardiomyocytes. Scale bars represent 1 μm.
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icant decreases of LV FS and LV EF 24 h after MDMA administration. The
LV developed pressure (LVDP) and +dP/dt markedly decreased in
MDMA-treated rats. In contrast, the increase in LV end-diastolic pres-
sure (LVEDP) was slight and τ was not affected, while−dP/dt signiﬁ-
cantly increased. τ is not a very sensitive index of diastolic function.
These results indicate that single MDMA administration induces signif-
icant LV systolic dysfunction andmarginal diastolic dysfunction.MDMA
also induced tachycardia, which peaked at 1 h after MDMA administra-
tion (452± 10 vs. 358± 7 beats/min in saline-injected rats, n= 6, P=
0.0002, Student t-test).3.2. MDMA induces autophagy
Western blot analysis showed that LC3-II and cathepsin-D levels in-
creased with time after MDMA administration (Fig. 1A). The ratio of
LC3-II to LC3-I also increasedmarkedly, but the LC3-I level was unaffect-
ed. Electron microscopic examination of the LV 24 h after MDMA ad-
ministration revealed the presence of autophagosome-like vacuoles
containing mitochondria or myelin-like structures (Fig. 1B).
MDMA signiﬁcantly decreased food intake in the 24 h after MDMA
administration, compared with that of saline-injected rats (Table 1).
Therefore, we examined saline-injected rats fed with similar amount
of food to MDMA-injected rats (18 g for 24 h). We found no change0
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LC3 and cathepsin-D levels (Fig. 1A). These results suggest that the
reduced feeding due to MDMA-induced anorexia did not contribute to
the induction of autophagy.3.3. MDMA activates AMPK-mTOR signaling
Western blots probed with antibodies speciﬁc to phosphorylation
sites of mTOR showed an increase in phosphorylation of mTOR at
Thr2446 (AMPK site), but not at Ser2448 (Akt site), with time until 24
h after MDMA administration (Fig. 2). Consistent with these ﬁndings,
AMPK phosphorylation peaked at 1 h after MDMA administration and
was sustained until 24 h, whereas Akt phosphorylation was unchanged
for 24 h after MDMA administration. Raptor, a mTOR component that
inactivates mTOR upon AMPK-mediated phosphorylation, was phos-
phorylated at Ser792 after MDMA administration (Fig. 3). Additionally,
phosphorylation of ULK1, another AMPK substrate and an ATG1 homo-
log, increased gradually from 1 h after MDMA administration (p-ULK1
level in Fig. 3). However, the ratio of phosphorylated to total ULK1
(p-ULK1 ratio) increased only at 1 h due to the time-dependent
increase in the total ULK1 level. Meanwhile, Compound C, an AMPK
inhibitor [22], abolished MDMA-induced mTOR phosphorylation at
Thr2446, and LC3-II upregulation (Fig. 4). These results suggest
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autophagosome clearance
The autophagicﬂux 24 h afterMDMAadministrationwas determined
by using autophagic inhibitors [15,16]. 3-MA abolished the MDMA-
mediated increases in LC3-II and cathepsin-D (Fig. 5A). Cathepsin-B and
beclin 1 also increased after MDMA administration in a 3-MA sensitive
manner, though did not reach the signiﬁcant levels (Fig. 5A). CQ, which
inhibits lysosomal clearance of autophagosomes, induced increases in
LC3-II and cathepsin-D in saline-injected rats, but did not affect the
MDMA-mediated increases in these proteins (Fig. 5B). Similarly, p62
level, a latemarker of autophagy, increased 24 h afterMDMAadministra-
tion, and this increase was not affected by CQ. These results indicate that
MDMA enhances both formation and accumulation of autophagosomes.3.5. MDMA causes cardiomyocyte damage through
lysosome destabilization
Western blot analysis of the cytosolic fraction showed release of
cathepsin-D and cathepsin-B into this fraction 24 h after MDMALC3-I
LC3-II
MDMA Saline MDMASaline
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Fig. 4. Effects of AMPK inhibitor on MDMA-induced autophagy. Representative western blots a
Thr2446 and LC3-II were determined as percentages of the value for saline-injected rats. Actin
injected rats; ††P b 0.01 vs. MDMA-injected rats (Tukey–Kramer test).administration (Fig. 6A). Notably, 3-MA suppressed the levels of cathep-
sins in the cytosol, suggesting a link of autophagy activation to the
increases in cytosolic cathepsins. Electron microscopy (Fig. 6B) showed
unusual large vacuoles that may have been caused by elimination of or-
ganelles (panel B1), lysis of myoﬁbrils (panel B2), and the myelin-like
structures inside and outside of capillaries (panel B3), suggesting myo-
cardial injury by lysosomal proteases. Consistent with the ﬁnding of
myoﬁbril lysis, degradation of cTnI was detected by western blotting
(Fig. 6C). The 22 kDa (band 1), 16 kDa (band 2) and 11 kDa (band 3)
bands increased with time after MDMA administration. Palmer et al.
demonstrated that cTnI fragment bands (corresponding to bands 2 and
3, but not band 1, in the current study) increased depending on the du-
ration of ischemia in ischemia-reperfused rat hearts, but did not identify
the protease [32]. Assuming involvement of the autophagy-lysosomal
pathway in the proteolysis, we examined the effect of 3-MA, CQ and a
relatively speciﬁc cathepsin inhibitor E64 on the increase in the density
of band 2 (Fig. 6D). Twenty-four hours after MDMA administration,
band 2 increased by 2-fold compared with saline-injected rats, and this
increase was suppressed by 3-MA, CQ or E64.
Cytosolic cathepsins can activate pro-apoptotic proteins, Bid [33,34]
and Bax [35], by cleavage. The activated Bax translocates from theMDMA Saline MDMASaline
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MDMA administration (Fig. 7A,B). In contrast, MDMA increased the
level of truncated Bid (tBid) signiﬁcantly and CQ or E64 blocked this in-
crease (Fig. 7C). Despite the Bid truncation, cleaved caspase-3, a well-
known indicator of apoptosis, was not detected in the 24 h after
MDMA administration (data not shown). Bid is also a substrate of
caspase-8 in the Fas apoptotic signaling pathway [36], but activation
of caspase-8 (cleaved caspase-8) was not detected after MDMA admin-
istration (data not shown). In postischemic reperfused hearts, activated
calpain can induce apoptosis through Bid cleavage [37] and necrosis
through fodrin proteolysis [38]. However, MDMA did not increase the
level of the 150 kDa fodrin breakdown product (Fig. 7D). Meanwhile,
Bcl-2 is an anti-apoptotic Bcl-2 family protein and activated by phos-
phorylation at Thr56 [39]. However, such phosphorylation was not de-
tected after MDMA administration (data not shown).
Changes in expression or phosphorylation of SR-Ca2+ regulatory
proteins underlie contractile dysfunction in various heart diseases
under the inﬂuence of sympathetic nerve activation [40,41]. However,
MDMA did not alter expression of phospholamban (PLN), ryanodine
receptor (RyR) and sarco/endoplasmic reticulum Ca2+ ATPase 2
(SERCA2a) (Supplementary material online, Fig. S1). Phosphorylation
of PLN at Thr17 and Ser16 transiently 1–6 h after MDMA injection, but
returned to baseline by 24 h. MDMA did not affect phosphorylation of
RyR at Ser2808.
3.6. Autophagic and lysosomal inhibitors improve MDMA-induced
contractile dysfunction
We examined whether 3-MA, CQ and E64 improved systolic dys-
function 24 h after MDMA administration. These three inhibitors
prevented distension in LV ESD and LV ESV, improved LV FS and LV EF
(Fig. 8A), and also improved LVDP and ±dP/dt 24 h after MDMAadministration (Table 2). CQ treatment of saline-injected rats induced
moderate accumulation of autophagosomes (Fig. 5B), but did not affect
systolic function (Fig. 8A). Compound C blocked autophagic activation
through AMPK-mTOR pathways (Fig. 4), and improved MDMA-
induced systolic dysfunction (Fig. 8B).
3.7. Measurement of MDMA metabolites
Cardiotoxic MDMAmetabolites, DHMA and DHA [10,11], are detect-
able in serum by 1 h afterMDMA administration,with a peak at 4 h, and
MDMA is consumed gradually by 24 h in humans [42] and rat [43]. Con-
sistent with a previous report that DHMA is the major metabolite of
MDMA in humans [44], we found abundant DHMA but little DHA in
serum from rats 4 h after MDMA administration (Supplementary mate-
rial online, Table S1).
4. Discussion
Single MDMA administration enhanced autophagy induction and
damaged the autolysosomal degradation system by lysosome destabili-
zation, resulting in accumulation of autophagosomes. 3-MA inhibited
accumulation of autophagosomes and improved MDMA-induced LV
contractile dysfunction. Accumulation of autophagosomes in cardiac
disorder has been shown in various situations. Lysosome-associated
membrane protein-2 (LAMP-2)-deﬁcient mice, a model of Danon's dis-
eases, show accumulation of autophagic vacuoles in cardiomyocytes,
contractile dysfunction and cardiomyopathy [45]. Autophagy is activat-
ed in ischemia-reperfused mouse heart by coronary occlusion, but
autophagosome clearance is impaired by ROS-mediated LAMP-2 down-
regulation, which causes cell death [46]. Ethanol intake also enhances
autophagy, leading to accumulation of autophagosomes and cardiac
contractile dysfunction [22,23]. However, the mechanism through
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is unclear. We found that the lysosomal inhibitor CQ did not affect
MDMA-induced autophagosome accumulation, but improved MDMA-
induced contractile dysfunction. Single administration of CQ induced
autophagosome accumulation, but maintained normal cardiac contrac-
tility. Theseﬁndings suggest that the direct cause of contractile dysfunc-
tion is not autophagosome accumulation per se.
We found thatMDMA induces release of lysosomal proteases into the
cytosol and promotes myoﬁbril damage and cTnI proteolysis. Previous
studies on hearts of patients with acute myocardial infarction [47] and
on ischemia-reperfused rat hearts [32] have revealed cTnI degradation,but did not identify the proteases involved. The sizes of cTnI fragments
are similar inMDMA treatment and ischemia–reperfusion [32]. The den-
sity of band 2 or 3, or the sum of these densities, is inversely correlated
with LVDP after reperfusion [32]. Lysosomal proteases are implicated in
the activation of cytosolic pro-apoptotic proteins such as Bax [35] and
Bid [33,34], and cathepsin inhibition attenuates apoptosis in the early
phase [48]. We also detected truncated Bid after MDMA administration.
Lysosomal proteases are optimally active at quite acidic pH (3.8–5.0), but
these ﬁndings suggest that these proteases retain their activity after cy-
tosolic release. We found that two lysosomal inhibitors, CQ and E64c,
inhibited cTnI proteolysis and Bid truncation and improved systolic
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Table 2
Effects of autophagic and lysosomal inhibitors on left ventricular pressure parameters 24 h after MDMA administration.
Saline MDMA 3-MA + MDMA E64 + MDMA
LVDP (mmHg) 91.5 ± 5.8 †† 57.7 ± 6.2 ⁎⁎ 81.4 ± 4.2 † 78.6 ± 2.3 †
+ dP/dT (mmHg/s) 6629 ± 681 †† 2933 ± 550 ⁎⁎ 5880 ± 562 † 5257 ± 239 †
− dP/dT (mmHg/s) −4834 ± 525 †† −2086 ± 603 ⁎⁎ −4713 ± 632 † −3793 ± 395
Parametersweremeasured 24h afterMDMA injection following each inhibitor treatment. Data are presented asmeans±SE (n=5). **P b 0.01 vs. saline-injected rats; †P b 0.05, ††P b 0.01
vs. MDMA-injected rats (Tukey–Kramer test).
699K. Shintani-Ishida et al. / Biochimica et Biophysica Acta 1842 (2014) 691–700function afterMDMA administration. CQ neutralizes the lysosomal/vacuolar
pH, thereby inhibiting lysosomal protease activity. Therefore, CQ can
inhibit lysosomal enzymes even after lysosome destabilization. E64c,
an inhibitor of cysteine proteases, inhibits calpain as well as cathepsins.
However, the lack of fodrin breakdown ruled out the contribution of
calpain. 3-MAblocked the increases in cytosolic cathepsin-D and -B levels,
cTnI proteolysis, and contractile dysfunction after MDMA administration.
These results suggest that cathepsins released from MDMA-activated
lysosomes damage myoﬁbrils and induce contractile dysfunction.
MDMA enhanced autophagy through activation of AMPK-mTOR sig-
naling. We found that AMPK phosphorylation and tachycardia peaked
at 1 h after MDMA administration. AMPK is a cellular energy sensor
and is activated by cellular stresses that decrease ATP content. In rat
heart, AMPK is phosphorylated depending on the intensity of exercise
10min after treadmill running [49]. Akt does not change after the exer-
cise, as also foundwithMDMAadministration.Matsui et al. showed that
ischemia stimulates autophagy through an AMPK-dependent mecha-
nism, whereas ischemia–reperfusion stimulates autophagy through a
beclin-1-dependent, but AMPK-independent, mechanism [50]. Consis-
tent with this, MDMA did not have a prominent affect on beclin-1 ex-
pression. These ﬁndings suggest that AMPK may be activated by
tachycardia and contributes to autophagy activation after MDMA ad-
ministration. Besides this effect on AMPK-mTOR signaling, MDMA up-
regulated the expression level of ULK1, which has recently been
reported to be involved in autophagy induction through transcriptional
upregulation by the tumor suppressor p53 [51].
Repeated binge administration ofMDMA (9 mg/kg i.v. twice daily for
4 days) induces diastolic contractile dysfunction in rats [6], which is in-
consistent with the reduction of systolic contractility after single admin-
istration (20 mg/kg i.p.) in the present study. Binge administration of
MDMA increases nitrotyrosine-containing proteins, including troponin-
T, tropomyosin α-1 chain, myosin light polypeptide, myosin regulatory
light chain, mitochondrial complex III and V, and sarcoplasmic reticulum
calciumATPase.We also observed an increase in nitrotyrosine content in
heart tissues, but increased nitrotyrosine could not be detected in any of
these proteins 24 h after singleMDMA administration (data not shown).
In addition, we found no relationship between SR-Ca2+ regulatory pro-
teins, including PLN, RyR and SERCA2a, and LV contractile dysfunction
24 h after MDMA administration. MDMA also induces activation of the
central and sympathetic nervous systems, leading to cardiovascular
events including tachycardia, hypertension and arrhythmia, and possible
death. However, these nervous systems are unlikely to contribute to LV
contractile dysfunction 24 h after MDMA administration because HR
[52] and PLN phosphorylation [53] increased at 1–6 h after MDMA ad-
ministration and returned to basal levels by 24 h.
In conclusion, the results of this study show for the ﬁrst time that
MDMA causes lysosome destabilization following activation of the
autophagy-lysosomal pathway, with subsequent release of lysosomal
proteases that damage myoﬁbrils and induce LV systolic dysfunction
in rat heart.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.01.013.Disclosures
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